Drug-induced liver injury (DILI) is rare compared to the worldwide frequent acute or chronic liver diseases. Therefore, patients included in series of suspected DILI are at high risk of not having DILI, whereby alternative causes may confound the DILI diagnosis. The aim of this review is to evaluate published case series of DILI for alternative causes.
Introduction
Accuracy is required to characterize drug-induced liver injury (DILI) correctly with its clinical features. DILI is not a single disease entity but bundles multiple patterns with variable clinical manifestations, caused by numerous drugs with different chemical structures [1, 2] . There have been many attempts in the scientific literature to describe the complexity and diversity of DILI. Among these are risk factors such as genetic susceptibility by human leucocyte antigen alleles [2] , comedication [3] , alcohol use [3, 4] , preexisting chronic liver diseases [4] , drug lipophilicity, high metabolic rates and daily doses of drugs [5, 6] , and for the diagnosis the disputed value of liver histology [7] . Other aspects of interest include characteristic DILI features [8] [9] [10] and epidemiology data [11] .
A critical analysis of the most implicated agents pointed out case reports on DILI are often not well described and critical clinical information is frequently lacking [12] . In addition, the reports often did not provide the information needed to determine the cause(s) of the liver injury. Furthermore, reviewers and editors did not pay sufficient attention to the completeness of the submitted case report for publication. Once the case report is published, it is widely but sometimes wrongly considered that the drug is hepatotoxic [12] . Overall, the documentation quality of DILI in the scientific medical literature is variable and more specifically, the exclusion of nondrug causes was recognized as a crucial element in the diagnostic process [12] .
In this systematic review article, we searched for global case series of suspected DILI, which concomitantly published alternative causes, and we analysed why DILI in a significant number of cases reported is not DILI but another liver disease, a biliary disease, or even a nonhepatic disease.
Methods

Literature search
Relevant published global case series of suspected DILI including concomitantly presented alternative causes were identified using a computerized search of the Medline database that included publications from 1993 to 31 October 2017. The following terms were considered: drug hepatotoxicity, drug induced liver injury and hepatotoxic drugs, combined with diagnosis, causality assessment and alternative causes. For each term, we focused on the first 100 publications representing single case reports, case series, review articles or letters to the editor. The reference lists of the retrieved publications were hand searched for additional publications.
Subsequently, we reviewed selected reports relevant to the aim of our study and retrieved 112 English language publications related to DILI.
Publication selection
Our initial assessment showed that among initial 112 DILI publications, only 21 case series specifically addressed routinely the question of alternative diagnoses in suspected DILI cases. Alternative causes were provided in these 21 publications as confirmed diagnoses, whereas cases with causality gradings of excluded, unlikely, unrelated or possible for an individual drug implied that alternative causes existed but were not considered as diagnoses. None of these 21 DILI publications was now reanalyzed using a causality assessment method (CAM) such as the preferred updated Roussel Uclaf Causality Assessment Method (RUCAM) [9] . Indeed, the published alternative causes were based on CAMs applied already by the authors, making a re-analysis and asking for original case data unnecessary.
Results
The principal goal was to assess the frequency and the type of published alternative causes in the 21 articles of the global case series (Table 1) . All reports published a variable number of cases with suspected DILI that were not DILI. In 18 out of 21 DILI articles, causality for individual drugs was assessed by the original authors (Table 1) , using RUCAM [8, 9] .
Alternative causes
Not all liver injury cases considered initially as DILI were indeed DILI cases when patients were better investigated and CAMs applied to verify or exclude causality (Table 1) . However, the articles addressing the issue of alternative causes are still limited despite abundant publications on DILI in the scientific literature. Problems of the 21 publications with variables confounding the DILI diagnosis obviously became evident during case assessment or re-evaluation prior to submission to the journal, recognized and published by the authors of the original reports .
Frequency
The 21 publications reported on 13 335 cases (Table 1 ) . In 4555/13 335 cases (34.2%), alternative causes were published, which indicated that in more than one-third there was a potential alternative explanation to the liver injury. The 13 335 cases have been reported from different areas and countries, with most cases originating from Europe, some from the USA and fewer from Asia (Table 1) .
Throughout the reports, the percentage of alternative diagnoses in case series was in a range of 3-50%.
Type of alternative diagnoses
Alternative causes were specified in most published reports (Table 1) , and in the remaining publications they were only globally quantified without diagnosis specification (Tables 1  and 2 ). The 327 cases with specified nondrug causes are listed in Tables 2 and 3 .
Biliary diseases
Biliary diseases were among the most alternative diagnoses, accounting for almost 12% (Table 3 ). These included, for instance, biliary obstruction, cholangitis, and choledocholithiasis (Table 2) . Such biliary diseases can be harmful for the patients, in whom the correct therapy was withheld or delayed. Among other unrecognized biliary diseases were primary biliary cholangitis and primary sclerosing cholangitis (Table 2) , for which specific therapy options are available.
Liver diseases
A broad spectrum of liver diseases unrelated to drugs remained undetected (Tables 2 and 3 ). For instance, missed diagnoses were mainly hepatitis B, C and E, rarely hepatitis by cytomegalovirus and Epstein-Barr virus (Table 3) . Autoimmune hepatitis is another example of a missed diagnosis, which requires a steroid therapy (Tables 2 and 3) . Interestingly, hepatitis A virus diagnosis was not missed in any of the publications (Tables 2 and 3 ). Genetic liver diseases such as haemochromatosis or Wilson disease were rare alternative diagnoses, as opposed to the more frequent nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, and alcoholic liver disease (ALD), which all together account for 10.4% of the alternative causes (Table 3) . Distinction from DILI is usually quite easy on the basis of careful analysis and clinical context. Total n = 13 335 n = 4555 34.2%
Listing of the 21 reports with published alternative causes in initially suspected DILI cases . Causality assessment methods refer to RUCAM (Roussel Uclaf Causality Assessment Method) [8, 13] ; the MV scale of Maria and Victorino; and the method of DILIN (Drug-Induced Liver Injury Network). Symbols: + signifies that alternative diagnoses were specified for all respective cases, +/-for some cases, and -for none of the cases. CN, China; DILI, drug-induced liver injury; ES, Spain; FR, France; NA, not available or not assessed; SE, Sweden Table 2 Alternative causes of initially suspected drug-induced liver injury (DILI) cases
Alternative causes
• Hepatitis B
Hepatitis B cirrhosis 1/138 cases [15] .
• Hepatitis B or C Chronic hepatitis B or C 28/801 cases [30] .
• Hepatitis C Acute hepatitis C 4/254 cases [24] ; Chronic hepatitis C 2/40 cases [22] .
• Hepatitis E 10/45 cases [21] , 9/318 cases [26] .
• CMV Hepatitis 2/138 cases [15] .
• EBV Hepatitis 2/138 cases [15] .
• Viral hepatitis
Unspecified viral hepatitis 2/91 cases [13] , 5/215 cases [16] , 11/570 cases [18] .
• Ischaemic hepatitis [25] .
• Primary biliary cholangitis 3/114 cases [19] .
• Primary sclerosing cholangitis 3/114 cases [19] .
• Haemochromatosis 1/91 cases [13] , 1/40 cases [22] .
• Wilson disease 1/215 cases [16] , 1/570 cases [18] .
• Gilbert syndrome 3/138 cases [15] .
• Fatty liver Steatosis 3/138 cases [15] , 1/95 cases [17] ; Non-alcoholic fatty liver disease 5/114 cases [19] .
• Nonalcoholic steatohepatitis 5/215 cases [16] , 4/570 cases [18] .
• Alcoholic liver disease • Liver injury by other comedication 19/73 cases [27] .
• Paracetamol overdose 2/138 cases [15] , 2/474 cases [25] .
(continues) 
• Benign recurrent intrahepatic cholestasis 1/254 cases [24] .
• Unspecified hepatobiliary diseases 163/425 cases [33] .
• Biliary diseases • Cardiac hepatopathy
Cardiac failure 1/91 cases [13] , 3/95 cases [17] , 1/20 cases [28] .
• Thyroid hepatopathy Hypothyroidism 1/215 cases [16] , 2/570 cases [18] ; Thyrotoxicosis 1/138 cases [15] .
• Rhabdomyolysis 1/95 cases [17] .
• Polymyositis 1/254 cases [24] .
• Postictal state 2/138 cases [15] .
• Osseous disease
Bone fractures 1/20 [28] ; Bone metastases 1/20 cases [28] .
• Tumour 11/110 cases [14] , 3/215 cases [16] , 10/570 cases [18] ; Metastatic bladder cancer 1/95 cases [17] ; Liver metastasis from carcinoid tumour 1/114 cases [19] .
• Lymphoma 2/138 cases [15] .
• Systemic sepsis 2/110 cases [14] , 12/138 cases [15] , 1/215 cases [16] , 3/570 cases [18] ; 2/20 cases [28] .
• Chlamydial infection 1/91 cases [13] .
• HIV infection
End-stage HIV disease 1/95 cases [17] .
• Past liver transplantation
Transplant related complications 17/110 cases [14] ;
Liver or bone marrow transplant prior to DILI onset 2/474 cases [25] .
• Unknown/unspecified liver diseases/various diseases Unspecified liver diseases 3/254 cases [24] ; Abnormal liver biochemical tests 3/40 cases [22] ; Isolated γ-glutamyltransferase increase 1/95 cases [17] ; viral hepatitis, chronic liver diseases, other liver disorders 1947/4165 cases [29] ; flare up of underlying liver disease due to hepatitis B and C, autoimmune hepatitis, unsuspected biliary obstruction, multiple medication, sepsis, transfusions 50/1091 cases [31] ; viral hepatitis, alcoholic hepatitis, autoimmune liver diseases, metabolic disorders, and other liver diseases 1943/3928 cases [32] .
(continues)
Rare alternative causes
In rare instances, increased serum bilirubin values in the absence of abnormal liver tests (LTs) had been attributed erroneously to DILI and not to Gilbert syndrome (Table 3 ). For hypothyroidism, thyrotoxicosis, rhabdomyolysis, polymyositis and postictal state, abnormal liver tests were misinterpreted as DILI (Tables 2 and 3 ). Most disturbingly, increased values of alkaline phosphatase were not attributed to the underlying bone diseases with fractures or metastases but wrongly to DILI of cholestatic type (Tables 2 and 3 ). Heavily misdiagnosed were also patients with malignancies including lymphoma accounting for almost 9% of the alternative causes, and sepsis for 6% (Table 3) . Not further evaluated for the quantitative analysis (Table 3) were cases of publications listed as unspecified hepatobiliary diseases (Table 2) . Excluded were viral hepatitis, alcoholic hepatitis, autoimmune liver diseases, metabolic disorders and unspecified diseases, all lacking case quantification (Table 2) .
Causality assessment methods
Among the 21 publications reporting alternative causes in DILI series , 18 reports used RUCAM (Table 1 ) [8] . The preference for RUCAM is in line with its use for evaluations by regulators, registries, case series, and case reports [9] . Other CAMs were rarely applied, such as the Maria and Victorino scale, the DILIN method or the Naranjo scale (Table 1 ). All three methods have major shortcomings [3, 9] . In one report [29] , no specific CAM was used (Table 1) , suggesting that 4165 cases including the cases due to alternative causes were probably assessed by global introspection [29] , with known limitations of this subjective approach [3, 9] .
Alternative diagnoses as confounding variables
As early as in 1993 and for the first time (Table 1) with RUCAM, a valid search for diagnoses as alternatives to DILI was feasible [8, 9, 13] , confirmed in the RUCAM updated in 2016 [9] . Progress in search for alternative causes was made in other studies published in 1999 [14, 15] and in subsequent years in reports using RUCAM (Table 1) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] .
Diagnostic flow diagram
A step forward was the early introduction of a diagnostic flow diagram for a quick overview [15] . The initial cohort study consisted of 110 patients as having DILI, in which 
Total alternative causes n = 327 100%
Data are derived from Table 2 , which also provides respective references.
RUCAM-based evaluation identified alternative causes in 42 patients and a possible DILI in 68 patients. Among those, 18 patients showed no relation with any drug, and the remaining 50 patients had DILI, which was caused by overdosed drugs in six patients, leaving 44 patients with idiosyncratic DILI [15] . Several characteristics differentiate these two forms of DILI, considering that the idiosyncratic DILI is the commonly used term for DILI in short [3, 9] . All alternative diagnoses are mentioned in the text, which also provides exact case numbers [15] . A similar approach of a diagnostic flow diagram was made in a subsequent report of suspected DILI involving statins [27] . This flow chart started with 239 reports of hepatic adverse effects related to statin therapy and eliminated cases due to insufficient information on aspartate transaminase or alanine transaminase <5× upper limit of normal. Finally, published RUCAM-based causality assessment revealed that 71% of the cases had a possible causal relationship and only 29% a highly probable or probable causal relationship [27] .
In another study [32] , the flow diagram presented a list of excluded cases with diagnoses of viral hepatitis, alcoholic hepatitis, autoimmune liver disease, metabolic disorders, and other causes of liver diseases, but there is little diagnostic specification and no quantification of cases with individual alternative diagnosis, although cumulatively 1943 cases of alternative causes can be calculated.
Quality of alternative diagnoses
Among the 21 publications, alternative causes remained unspecified in three articles, but case numbers were presented (Table 1) [25, 27, 29] . In seven reports, valid alternative diagnoses were available for some cases (Table 1) [20] [21] [22] [23] [31] [32] [33] . In 12 publications, all alternative causes were described ( Table 1 ). The diagnoses in this group consisting of 328 patients were available for further assessment (Tables 2 and 3) including the proportion of each diagnosis or category of diseases among this cohort [3-19, 24, 26, 28] .
Verified real DILI cases
Overall, in the cohort of suspected 13 335 DILI cases, around one-third were attributable to alternative diagnoses (Table 1 ) . However, this does not mean that all remaining cases were necessarily DILI, since causality was partially questioned or even excluded [34] . For instance, some cases reached only a possible causality level for a drug, which should have excluded such cases from the group of actual DILI. Another problem is the poor data quality with limited details required for a valid causality assessment . This shortcoming was also present in DILI cases in a previous study [34] or in a website [2] . The weaknesses are due to questionable reaction courses following drug cessation [13, [16] [17] [18] , issues of concomitant hepatotoxins [13] , drug intoxication leading to intrinsic liver injury but not to idiosyncratic DILI [2, 17, 25] , and to missing liver injury criteria [17, 18, 21, 25, 27] .
Based on the present study (Tables 1-3 ) and a previous report [34] , DILI case series could be divided into three different groups. The first group would include all cases with established causality for the suspected drug and hopefully be the group with the majority of cases. The second group will include all cases with alternative causes. The third group will consider all other cases, such as those with only possible relationship and all those with lacking any causality due to missing data. Therefore, results presented in DILI case series should be viewed critically, as DILI seems not always to be a valid DILI.
Discussion
It is obvious that alternative causes are frequently found while assessing DILI cases (Tables 1-3 ) . Therefore, epidemiological aspects of DILI as compared to CLD are of interest. Indeed, some countries or regions have high incidence and prevalence rates of liver diseases, a challenging background for patients with suspected DILI. In clinical practice, it is not unusual that patients under a drug therapy present with clinical signs of liver disease and/or abnormal LTs. Considering these conditions and having ruled out an acute viral hepatitis using conventional diagnostic tests, the physician may want to know whether the liver disease is more likely a DILI or a flare of a pre-existing chronic liver disease. An order of magnitude may be deduced from epidemiological characteristics of DILI as compared to chronic liver diseases in various regions.
Studies from China estimated that worldwide >1.3 billion individuals experience a liver disease, most commonly NAFLD (>600 million) and less frequently chronic hepatitis B virus (HBV; >350 million) as evidenced by HBsAg positivity or chronic hepatitis C virus (HCV; 200 million) as evidenced by anti-HCV positivity, and ALD (>150 million) [35] . For DILI, valid corresponding worldwide data are not available. In the USA, the prevalence rate of chronic liver diseases from various aetiologies is high in the population and accounts for 14.8% during the period 2005-2008 [35] . In this cohort, the prevalence is the highest for NAFLD (75.1%), compared to low rates for nonalcoholic steatohepatitis (1.1%), HBV (2.0%) and HCV infections (1.7%), ALD (14.8%), and hereditary hemochromatosis (0.3%). Prevalence data of acute DILI were not reported [35] . In a population-based study from the USA, the prevalence of liver cirrhosis was approximately 0.27%, corresponding to around 633 323 adults, with hepatitis C and alcohol as the most frequent causes [36] . Since DILI prevalence rate is not available in the USA, another approach is required using annual incidence data to get some order of magnitude [37] . Upon extrapolation from the populationbased French study with an annual estimated incidence of 13.9 cases per 100 000 inhabitants [17] , nearly 44 000 individuals in the USA will suffer from acute DILI each year [37] . Based on the prevalence of 14.8% in adults [35] and considering the US population of 323.2 million in 2016, around 47.8 million individuals would have chronic liver disease. This compares with the estimated 44 000 individuals experiencing DILI each year. These crude data imply that in the US population, chronic liver disease is much more frequent than DILI. In China, studies of 2012 in a Beijing hospital showed among a large cohort with various liver diseases the following distribution: hepatocellular carcinoma 34.4%, HBV 28.7%, HCV 24.8%, ALD 6.7%, DILI 4.2%, and autoimmune hepatitis 1.1% [38] . These data confirm that DILI is a rare liver disease even in a nonhepatocellular carcinoma cohort.
The large difference in frequency observed between DILI and chronic liver diseases suggests that abnormal LTs in patients under drug therapy are much more likely to be due to pre-existing chronic liver disease or another acute liver disease than to DILI, which is called background noise if not further evaluated. Therefore, physicians and other health care professionals have to keep in mind that many alternative diagnoses are to be carefully investigated and ruled out before considering DILI that remains a diagnosis of exclusion. Various approaches are of interest.
In case series and for the sake of clarity, a flow chart of cases excluded from an analysis should be provided (Figure 1 ). Overlooking alternative causes and missing the correct diagnosis in a setting of suspected DILI is a serious clinical flaw (Tables 1-3 ). When these issues are not correctly addressed in publications, reliable diagnostic questions can be raised in databases such as LiverTox [12] and in other reports [34] . Not recognizing nondrug causes inevitably leads to a delay in reaching the correct diagnosis, but little is known about the health consequences in these patients. In a clinical setting of patients with an acute liver injury, the diagnosis of DILI is much less likely than a chronic liver disease due to their high prevalence rates in most countries [35] [36] [37] [38] .
Figure 1
Suggestion for a flow chart of drug-induced liver injury (DILI) case series with excluded cases Drug induced liver injury: Alternative causes Consequently, a strong and systematic diagnostic approach is recommended to differentiate chronic liver diseases from DILI, as shown in Figures 1 and 2 [4, 39] .
In each patient with suspected DILI, a careful clinical evaluation and management is indispensable in search for the correct diagnosis and exclusion of alternative causes (Figure 2) . Such evaluation of a patient with suspected DILI should be supported by the use of a valid CAM like RUCAM in its updated version of 2016 [9] . The early use of RUCAM ensures prospective collection of key case data and data completeness. The list of differential diagnoses, which should be excluded or verified, is a kind reminder for the physician caring for the patient (Figure 2 ). Several listed diagnostic parameters are also key items of RUCAM [9] , which is also used in suspected herb-induced liver injury by herbal medicines, traditional Chinese medicine and dietary supplements [32, [40] [41] [42] [43] [44] [45] [46] . However, RUCAM cannot compensate for incorrect case data transfer by physicians from clinical charts to the RUCAM scale, conditions which must be avoided [43] [44] [45] .
Figure 2
Checklist of differential diagnoses in cases of suspected DILI. This tabular listing is adapted and derived from a previous publication [9] . Although not comprehensive, it is to be used as a guide and in connection with RUCAM [9] . AAA, anti-actin antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ASGPR, asialo-glycoprotein-receptor; BMI, body mass index; CT, computed tomography; CYP, cytochrome P450; DILI, drug-induced liver injury; PDH, pyruvate dehydrogenase; HAV, hepatitis A virus; HBc, hepatitis B core; HBV, hepatitis B virus; HCV, hepatitis C virus; HEV, hepatitis E virus; HIV; human immunodeficiency virus; LKM, liver kidney microsomes; LP, liver-pancreas antigen; LSP, liver specific protein; MRC, magnetic resonance cholangiography; MRT, magnetic resonance tomography; p-ANCA, perinuclear antineutrophil cytoplasmatic antibodies; PCR, polymerase chain reaction; RUCAM, Roussel Uclaf Causality Assessment Method; SLA, soluble liver antigen; SMA, smooth muscle antibodies; TSH, thyroid stimulating hormone; TTG, tissue transglutaminase Based on the finding that most published DILI reports lacked essential information such as exclusions of competing viral aetiologies, which were reported in <50% of the studies, suggestions have been made on the minimum number of elements that should be required for reporting individual cases of DILI in the literature [47] . Efforts to promote and include a list of essential diagnostic elements in research articles could increase the quality and clinical utility of published reports of DILI [47] . This proposal is supported by other reports [9] and the present study providing a list of differential diagnoses (Figure 2) .
Transparent documentation of complete case data is mandatory for publication, at least as supplementary files if space is restricted. However, among the published reports on liver injury cases, many journals allow long tables of case narratives and RUCAM based details of scored key items [40] [41] [42] [43] [44] [45] [46] . For instance, a recent report presented among other tables specifically two tables for all 26 patients, one for case narratives and the other one for RUCAM based details [40] . Not providing case details is a serious reason to disqualify many liver injury case reports and case series.
Clearly, RUCAM is the worldwide most commonly used CAM for DILI and herb-induced liver injury [9] and should be applied in future cases of suspected liver injury. This allows comparison among studies and countries.
Conclusion
There is considerable concern that in patients with suspected DILI, published alternative causes as variables can confound causality and put the DILI diagnosis in question. This was substantiated by an analysis of 13 336 cases of suspected DILI since, in more than one-third of the cases, alternative causes were found more likely, suggesting that the suspected DILI was probably not DILI. Since DILI is rare as compared to the high incidence and prevalence rates of chronic liver disease, abnormal liver tests in patients under a drug therapy are more likely to be caused by a pre-existing liver disease than by drugs leading to DILI. In addition, many features of DILI presented in the scientific literature are derived from publications of DILI cohorts with not secured DILI diagnosis. Future case series should focus on secured DILI diagnosis, to be established by prospective approach using the scored items of the validated RUCAM in its updated version. This method provides objective results of causality gradings for each drug, and it operates without experts' opinions that, by definition, are subjective and lack transparency.
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